Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients.
AUTOR(ES)
Alarcón, G S
RESUMO
OBJECTIVES--To determine the probability of drug continuation in a large cohort of methotrexate treated rheumatoid arthritis (RA) patients, the reasons for discontinuation of methotrexate, the overall survival of the members of this cohort, and the causes of death in these patients. METHODS--Yearly follow up was conducted in methotrexate treated RA patients who formed a cohort between 1981 and 1986 at a tertiary care centre. The probability of drug continuation and the patients' survival were calculated using standard statistical procedures; standardised mortality ratios were calculated using death certificate data and USA general population and mortality tables. RESULTS--The probability of methotrexate continuation at 10 years from the time the first members entered the cohort was 30%. Toxicity (and its severity) was the most frequent cause of discontinuing methotrexate. The cumulative probability of survival was 85% for women and 45% for men. A greater than expected number of deaths from infections was observed, but the number of deaths from cancer and cardiovascular diseases were within the range expected. CONCLUSIONS--Toxicity remains the most common cause for methotrexate discontinuation. Survival was comparable to that of other RA cohorts. Methotrexate may be implicated as an associated factor in the deaths from infections.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1009984Documentos Relacionados
- Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate.
- Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients.
- Controlled trial of methenolone acetate in prednisolone-treated rheumatoid arthritis patients.
- Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid.
- Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients.